The antibody-based drug Andembry is the first to target factor XIIa, a protein responsible for swelling in people with this ...

It usually affects people who are older. Only about 10 to 15 percent of those who have Parkinson’s disease have a family history of it. For the rest, the cause of Parkinson’s is usually unknown.

The U.S. Food and Drug Administration has approved Andembry (garadacimab-gxii) as the only treatment targeting factor XIIa ...

Genetic testing could prevent you from ever having ovarian cancer. “The only way to do that is to offer testing to people ...

Researchers looked at a gene that is critical to regulating the body’s iron levels. A common genetic variant is linked to a ...

CSL Behring’s Andembry is now approved as a subcutaneous, self-injection for hereditary angioedema (HAE) patients ages 12 and older and will be available by the end of June 2025.

Andembry is the first prophylactic therapy for hereditary angioedema to target factor XIIa, inhibiting the top of the ...

Garadacimab-gxii is the first and only treatment that targets factor XIIa (FXIIa) for the prophylactic prevention of hereditary angioedema (HAE) attacks in patients 12 years and older.